In part I, the trans palladium complex, trans-[Pd(Naph)2Cl2] (1), have been synthesized and characterized by elemental analysis, fourier transform infrared and nuclear magnetic resonance spectroscopy. Single crystal X-ray diffractometry has been used to determine crystal structure of 1. The interaction of the complex 1 and ligand with DNA was investigated using UV-Vis spectroscopy, fluorescence emission, circular dichroism and helix melting methods. The analysis results show that (1) and Naphazoline can interact with DNA via partial intercalation and groove binding mode. It was found the binding constant were 0.9 × 104 M-1 and 3.81 × 104 M-1 for Naphazoline and complex (1), respectively. DNA cleavage activity of complex (1) and Naphazoline was investigated; indicating that complex (1) promoted the cleavage of plasmid DNA at physiological conditions. Interaction with BSA and a competitive study in the presence of site marker drugs was performed using fluorescence emission spectroscopy. Based on the fluorescence data, the binding constant for ligand and complex (1) was 4.78×103 and 1.12×104 M-1, respectively and sites I and III were identified as BSA binding sites. In addition molecular docking studies have been conducted to investigate interaction of the DNA and BSA with ligand and complex (1). Finally, In vitro cytotoxicity of naphazoline and (1) were carried out against breast cancer (MCF-7) and cervical cancer (HeLa) cell lines. The results show cytotoxicity of (1) is more than Naphazoline. In part II, two palladacyclic, [Pd{(C,N)-C6H4NH(CH2CH3)}(NHC)] (2) and [Pd{(C,N)-C6H4NH2}(NHC)] (3), were prepared using binuclear palladium complexes and imidazolium salts as precursors of the N-heterocyclic carbene ligand (NHC) and characterized by elemental analysis and UV-Vis spectroscopic methods. The interaction of imidazolium salts and complexes (2) and (3) with DNA was investigated using UV-Vis and fluorescence emission, circular dichroism spectroscopy and viscosity. The results showed that imidazolium salts, complexes (2) and (3) interact with DNA, The results showed that imidazolium salts, complexes (2) and (3) interact with DNA, via groove and partial intercalation, respectively. BNA binding and competitive study in the presence of site marker drugs showed imidazolium salt, (2) and (3) bind to site I, I and II of BSA. Molecular docking method was used to investigate the interaction with DNA and BSA theoretically. In vitro evaluation of the anti-cancer properties of imidazolium salts and complexes against MCF-7 and cervical (HeLa) cell lines showed higher cytotoxicity of the compounds than cisplatin. In part III, magnetic nanocomposites containing manganese and graphene oxide nanoparticles were prepared. Subsequently, the third generation of polyamidoamine dendrimer was grown on the surface using methyl acrylate and ethylene diamine. In order to target drug release, end groups of trees were functionalized with folic acid. The resulting nanocomposites (m-GO-G3-F) were identified using spectroscopic and microscopic methods. To investigate the potential of nanocomposite as a drug nanocarrier, complex (1) was chosen as a drug model. Factors affecting complex loading (1) on nanocomposites including drug concentration, temperature, and loading time based on loading efficiency percentage and optimum entrapment efficiency and release in neutral and acidic media at 37 and 45 ° C. Was investigated. Based on the study of the release of complex (1) in the in vitro environment of the synthesized nanocarrier, the highest amount of complex was released in acidic medium at 45 ° C. In part IV, nanocomposite (m-GO-G3) was used as support for loading of Pd particles and was identified by various spectroscopic and microscopic methods. The final nanocomposite was used as a catalyst for the reduction reaction of nitro aromatic compounds. The reduction reactions were investigated using an ultraviolet-visible spectroscopy and in each reaction the pseudo-first-order rate constant was calculated. Based on the results, the highest rate constant was observed for the combination of 2,1-di-nitro benzene and the lowest nitro-phenylhydrazide. The catalyst was applied for up to 10 periods in the reaction of reducing paranitrophenol. In part V, complex (2) was immobilized on the reduced graphene oxide via non-covalent interactions and characterized by spectroscopic and microscopic methods. Also, its catalytic activity in the Suzuki-Miyaura coupling reaction and reduction of paranitrophenol to paranitrophenol was investigated. The results indicate the high activity of the hybrid against different aryl halides which the withdrawn electron group showed higher efficiency than the other. In the recyclability study, the catalyst was used up to 6 times without any significant reduction in efficiency.